Taken together, our data indicates that two immune checkpoint pathways, PD1/PD-L1 and TIM-3/Gal-9, are altered in COVID-19, and that specifically, sPD-L1 and sTIM-3 serum levels can differentiate between IMV and NIMV patients. Here, LGALS9 is linked to COVID-19.